A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
Latest Information Update: 26 Sep 2023
At a glance
- Drugs VP 301 (Primary)
- Indications Lymphoma; Myeloma; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 15 Sep 2023 Status changed to discontinued, according to ClinicalTrials.gov: US National Institutes of Health record.
- 03 Feb 2023 New trial record